NSC697923 |
| Catalog No.GC11932 |
NSC697923 est un puissant inhibiteur de l'UBE2N (enzyme de conjugaison de l'ubiquitine E2 N, Ubc13). NSC697923 induit la mort des cellules du neuroblastome (NB) en favorisant l'importation nucléaire de p53 dans les cellules NB de type sauvage p53. NSC697923 induit également la mort cellulaire dans les cellules NB mutantes p53 par activation de la voie apoptotique médiée par JNK. NSC697923 inhibe les dommages À l'ADN et la signalisation NF-κB. Activité antitumorale.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 343351-67-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
NSC697923 is a selective and permeable inhibitor of the ubiquitin-conjugating enzyme Ubc13-Uev1A which blocks the formation of ubiquitin thioester conjugate. And the small-molecule inhibitor inhibits proliferation and survival of diffuse large B-cell lymphoma cells (DLBCL) [1].
Diffuse large cell lymphoma is the most common lymphoma that has a rapid growth rate and causes masses infiltrating tissues or obstructing organs. Unless treated in time, it will kill people quickly.
NSC697923 is an potent inhibitor of the formation of the Ubc13 and NF-κB activation in DLBCL. There are constitutive NF-kB pathway activities in DLBCL. So, impeding NF-kB activation in DLBCL would be a good solution to inhibit the proliferation and survival of diffuse of DLBCL. Also, NSC697923 blocks the formation of the Ubc13-Uev1A by inhibiting the formation of the Ubc13_Ub conjugate while it is a key component for DLBCL grown. In the long term, the cell cannot survive without Ubc13 expression. In conclusion, compound NSC697923 is an efficient inhibitor of DLBAL survival [1,2].
In a xenograft mouse model, NSC697923 has significantly reduced the proliferation and survival of diffuse large B-cell lymphoma (DLBCL) cells and induces NB cell death [1,3].
References:
[1]. Pulvino M, Liang Y, Oleksyn D, et al. Inhibition of proliferation and survival of diffuse large B-cell lymphoma cells by a small-moleculeinhibitor of the ubiquitin-conjugating enzyme Ubc13-Uev1A. Blood, 2012, 120: 1668–1677.
[2]. Zhaojia Wu, Siqi Shen, Zhiling Zhang, et al. Ubiquitin-conjugating enzyme complex Uev1A-Ubc13 promotes breast cancer metastasis through nuclear factor-кB mediated matrix metalloproteinase-1 gene regulation. Breast Cancer Research, 2014, 16:75-90.
[3]. J Cheng, Y-H Fan, X Xu, et al. A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways. Cell Death and Disease, 2014, 54: 1079.
| Cell experiment [1]: | |
|
Cell lines |
Human NB cell lines with MYCN amplification (IMR-32, NGP and NB-19) and without (CHLA-255, SK-N-AS and SH-SY5Y) |
|
Preparation method |
The solubility of this compound in DMSO is >10mM. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reacting condition |
5μM ;24hours |
|
Applications |
Treatment with NSC697923 significantly reduced NB cells viability in a dose-dependent manner and inhibited both anchorage-dependent and -independent colony formation of NB cells. NSC697923 induced apoptosis in all NB cell lines tested. In addition, NSC697923 also induced apoptosis in p53 mutant NB cells by activation of JNK-mediated apoptotic pathway. NSC697923 exhibited its effect primarily through inducing p53 nuclear translocation but not increasing its total amount. NSC697923 treatment also induced more phosphorylation of JNK, p38, and ERK in SK-N-AS. |
| Animal experiment [2]: | |
|
Animal models |
5- to 6-week-old female athymic Ncr nude mice (SH-SY5Y and NGP xenografts) |
|
Dosage form |
5 mg/kg , intraperitoneal injection everyday for 10 days |
|
Application |
These results showed significant tumor regression in NSC697923 treatment group of both SH-SY5Y and NGP xenografts. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Cheng J, Fan YH, Xu X., et al. A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways. Cell Death Dis. 2014 Feb 20;5:e1079. |
|
| Cas No. | 343351-67-7 | SDF | |
| Chemical Name | 2-(4-methylphenyl)sulfonyl-5-nitrofuran | ||
| Canonical SMILES | CC1=CC=C(C=C1)S(=O)(=O)C2=CC=C(O2)[N+](=O)[O-] | ||
| Formula | C11H9NO5S | M.Wt | 267.26 |
| Solubility | Soluble in DMSO | Storage | Store at -20° C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.7417 mL | 18.7084 mL | 37.4167 mL |
| 5 mM | 0.7483 mL | 3.7417 mL | 7.4833 mL |
| 10 mM | 0.3742 mL | 1.8708 mL | 3.7417 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 28 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *